Genfit Competitors

Inhibrx (NASDAQ:INBX) and Genfit (NASDAQ:GNFT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.

Profitability

This table compares Inhibrx and Genfit's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and target prices for Inhibrx and Genfit, as reported by MarketBeat.com.

Inhibrx currently has a consensus price target of $34.6667, suggesting a potential upside of 98.89%. Genfit has a consensus price target of $43.60, suggesting a potential upside of 911.60%. Given Genfit's higher possible upside, analysts clearly believe Genfit is more favorable than Inhibrx.

Institutional & Insider Ownership

36.6% of Inhibrx shares are owned by institutional investors. Comparatively, 0.4% of Genfit shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Inhibrx and Genfit's gross revenue, earnings per share and valuation.

Inhibrx has higher earnings, but lower revenue than Genfit.

Summary

Genfit beats Inhibrx on 3 of the 5 factors compared between the two stocks.

DBV Technologies (NASDAQ:DBVT) and Genfit (NASDAQ:GNFT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.

Profitability

This table compares DBV Technologies and Genfit's net margins, return on equity and return on assets.

Risk & Volatility

DBV Technologies has a beta of 2.91, suggesting that its stock price is 191% more volatile than the S&P 500. Comparatively, Genfit has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and target prices for DBV Technologies and Genfit, as reported by MarketBeat.com.

DBV Technologies currently has a consensus price target of $7.25, suggesting a potential upside of 22.88%. Genfit has a consensus price target of $43.60, suggesting a potential upside of 911.60%. Given Genfit's higher possible upside, analysts clearly believe Genfit is more favorable than DBV Technologies.

Institutional & Insider Ownership

32.5% of DBV Technologies shares are owned by institutional investors. Comparatively, 0.4% of Genfit shares are owned by institutional investors. 15.3% of DBV Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares DBV Technologies and Genfit's gross revenue, earnings per share and valuation.

Genfit has higher revenue and earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Genfit, indicating that it is currently the more affordable of the two stocks.

Summary

Genfit beats DBV Technologies on 6 of the 11 factors compared between the two stocks.

Harpoon Therapeutics (NASDAQ:HARP) and Genfit (NASDAQ:GNFT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.

Profitability

This table compares Harpoon Therapeutics and Genfit's net margins, return on equity and return on assets.

Risk & Volatility

Harpoon Therapeutics has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500. Comparatively, Genfit has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and target prices for Harpoon Therapeutics and Genfit, as reported by MarketBeat.com.

Harpoon Therapeutics currently has a consensus price target of $31.75, suggesting a potential upside of 71.25%. Genfit has a consensus price target of $43.60, suggesting a potential upside of 911.60%. Given Genfit's higher possible upside, analysts clearly believe Genfit is more favorable than Harpoon Therapeutics.

Institutional & Insider Ownership

79.0% of Harpoon Therapeutics shares are owned by institutional investors. Comparatively, 0.4% of Genfit shares are owned by institutional investors. 34.9% of Harpoon Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Harpoon Therapeutics and Genfit's gross revenue, earnings per share and valuation.

Harpoon Therapeutics has higher earnings, but lower revenue than Genfit. Harpoon Therapeutics is trading at a lower price-to-earnings ratio than Genfit, indicating that it is currently the more affordable of the two stocks.

Summary

Genfit beats Harpoon Therapeutics on 8 of the 14 factors compared between the two stocks.

Athira Pharma (NASDAQ:ATHA) and Genfit (NASDAQ:GNFT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.

Profitability

This table compares Athira Pharma and Genfit's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and target prices for Athira Pharma and Genfit, as reported by MarketBeat.com.

Athira Pharma currently has a consensus price target of $42.50, suggesting a potential upside of 151.78%. Genfit has a consensus price target of $43.60, suggesting a potential upside of 911.60%. Given Genfit's higher possible upside, analysts clearly believe Genfit is more favorable than Athira Pharma.

Institutional & Insider Ownership

66.7% of Athira Pharma shares are owned by institutional investors. Comparatively, 0.4% of Genfit shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Athira Pharma and Genfit's gross revenue, earnings per share and valuation.

Athira Pharma has higher earnings, but lower revenue than Genfit.

Vaxart (NASDAQ:VXRT) and Genfit (NASDAQ:GNFT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.

Risk & Volatility

Vaxart has a beta of -0.11, suggesting that its stock price is 111% less volatile than the S&P 500. Comparatively, Genfit has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500.

Valuation and Earnings

This table compares Vaxart and Genfit's gross revenue, earnings per share and valuation.

Vaxart has higher earnings, but lower revenue than Genfit. Vaxart is trading at a lower price-to-earnings ratio than Genfit, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

17.9% of Vaxart shares are owned by institutional investors. Comparatively, 0.4% of Genfit shares are owned by institutional investors. 7.3% of Vaxart shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Vaxart and Genfit's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and target prices for Vaxart and Genfit, as reported by MarketBeat.com.

Vaxart currently has a consensus price target of $15.00, suggesting a potential upside of 204.88%. Genfit has a consensus price target of $43.60, suggesting a potential upside of 911.60%. Given Genfit's higher possible upside, analysts clearly believe Genfit is more favorable than Vaxart.

Summary

Genfit beats Vaxart on 8 of the 14 factors compared between the two stocks.

MeiraGTx (NASDAQ:MGTX) and Genfit (NASDAQ:GNFT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings and institutional ownership.

Risk & Volatility

MeiraGTx has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500. Comparatively, Genfit has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500.

Valuation & Earnings

This table compares MeiraGTx and Genfit's gross revenue, earnings per share (EPS) and valuation.

MeiraGTx has higher earnings, but lower revenue than Genfit. MeiraGTx is trading at a lower price-to-earnings ratio than Genfit, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

56.4% of MeiraGTx shares are held by institutional investors. Comparatively, 0.4% of Genfit shares are held by institutional investors. 16.5% of MeiraGTx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares MeiraGTx and Genfit's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for MeiraGTx and Genfit, as reported by MarketBeat.

MeiraGTx currently has a consensus target price of $33.00, suggesting a potential upside of 148.68%. Genfit has a consensus target price of $43.60, suggesting a potential upside of 911.60%. Given Genfit's higher possible upside, analysts plainly believe Genfit is more favorable than MeiraGTx.

Summary

Genfit beats MeiraGTx on 7 of the 13 factors compared between the two stocks.